Thalassemia epidemiology and demographics
Thalassemia epidemiology and demographics On the Web
American Roentgen Ray Society Images of Thalassemia epidemiology and demographics
Overall, thalassemia is a rare condition with a low incidence and prevalence in the United States. However, non-US countries have a higher incidence and prevalence. These include countries of the Mediterranean basis and Southeast Asia. The exact incidence and prevalence are unknown, but various estimates have been reported.
Epidemiology and Demographics
- The incidence of thalassemia is about 300,000 to 400,000 per year. 
- The incidence of beta-thalassemia is 42,000 per year.
- Worldwide, the prevalence of thalassemia 3000 per 100000.
- The estimated prevalence of thalassemia worldwide is 300,000,000
- The estimated prevalence of thalassemias is 16% in people from Cyprus, 3-14% in Thailand, and 3-8% in populations from India, Pakistan, Bangladesh, Malaysia and China. There are also prevalences in descendants of people from Latin America, and Mediterranean countries (e.g. Spain, Portugal, Italy, Greece and others). A very low prevalence has been reported from people in Africa (0.9%), with those in northern Africa having the highest prevalence, and northern Europe (0.1%). Thalassemia is the most common monogenic disease in Iran.
- The carrier rate of beta-thalassemia in Cyprus is estimated to be 12,000 to 15,000 per 100,000 persons.
- The carrier rate of beta-thalassemia in Greece is estimated to be 7,400 per 100,000 persons.
- The carrier rate of beta-thalassemia in Turkey is estimated to be 600 to 13,000 per 100,000 persons.
- In Turkey, approximately 1.6 million people (of 80 million) have thalassemia trait.
- In Turkey, approximately 5,500 people are homozygous for thalassemia.
Thalassemia affects men and women equally, since this is a disease with autosomal recessive, not sex-linked, inheritance.
- Higgs DR (2013). "The molecular basis of α-thalassemia.". Cold Spring Harb Perspect Med. 3 (1): a011718. PMC . PMID 23284078. doi:10.1101/cshperspect.a011718.
- Negre O, Eggimann AV, Beuzard Y, Ribeil JA, Bourget P, Borwornpinyo S; et al. (2016). "Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.". Hum Gene Ther. 27 (2): 148–65. PMC . PMID 26886832. doi:10.1089/hum.2016.007.
- Liaska A, Petrou P, Georgakopoulos CD, Diamanti R, Papaconstantinou D, Kanakis MG; et al. (2016). "β-Thalassemia and ocular implications: a systematic review.". BMC Ophthalmol. 16: 102. PMC . PMID 27390837. doi:10.1186/s12886-016-0285-2.
- Waheed F, Fisher C, Awofeso A, Stanley D (2016). "Carrier screening for beta-thalassemia in the Maldives: perceptions of parents of affected children who did not take part in screening and its consequences.". J Community Genet. 7 (3): 243–53. PMC . PMID 27393346. doi:10.1007/s12687-016-0273-5.
- Adib-Hajbaghery M, Ahmadi M, S P (2015). "Health Related Quality of Life, Depression, Anxiety and Stress in Patients with Beta-Thalassemia Major.". Iran J Ped Hematol Oncol. 5 (4): 193–205. PMC . PMID 26985352.
- De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M; et al. (2017). "β-Thalassemia Distribution in the Old World: an Ancient Disease Seen from a Historical Standpoint.". Mediterr J Hematol Infect Dis. 9 (1): e2017018. PMC . PMID 28293406. doi:10.4084/MJHID.2017.018.